Biologics have numerous benefits when developed as therapeutics. During her recent presentation hosted by Metrion Biosciences, Cath Hutchings discusses the potential held by ion channel targeting antibodies.
Early-stage engineering biology companies are welcome to register their interest to pitch at the UK Bioscience Forum.
On Thursday the Department of Health (DHSC) announced its procurement exercise for an express freight service contract to deliver medicines and medical supplies into the country in the event of a no-deal Brexit. This new £25m contract is intended to deliver small parcels of medicines or medical products on a 24-hour basis, with additional provision to move larger pallet quantities on a two to four-day basis. The contract will run for 12 months, with a possible further 12-month extension. The contract notice has been published in the Official Journal of the European Union and potential bidders have until August 21 to submit proposals, with the successful provider or providers likely to be announced in September.
The BIA has published a new guide for members on the supplementary protection certificate (SPC) manufacturing waiver, which has recently been introduced in the EU. Here, the lead author, Andrew Hutchison, explains why the BIA’s IP Advisory Committee has produced the guide.
In this fifth edition in our blog series on the 2019 Spending Review, BIA’s Policy and Public Affairs Manager Eric Johnsson looks at what the recently announced fast-tracked spending round means for our sector.
It feels like the new Government has been making an announcement a day this August! My blog this week highlights the seven key announcements for our sector in the last week, so sorry it’s longer and denser than normal, especially if you are picking this up after a holiday.
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
Inovotion seek academic or industry partners able to provide diverse immuno-oncology (IO) compounds, with preclinical data available, to validate their in ovo model.
Simomics seek collaborators with in silico disease models with 3Rs benefits, to be enhanced through Virtual Disease Laboratories.
HistologiX joins the BioHub community from July 2019 as a tenant and will have an increased presence in the BioCity Group community with a new location for establishing new networks and connections.